GSK4532990 for Alcohol-related Liver Disease

(STARLIGHT Trial)

Recruiting at70 trial locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: GlaxoSmithKline

Prior Safety Data

Trial Summary

What is the purpose of this trial?

The goal of this study is to assess the safety and efficacy of GSK4532990 in participants with alcohol-related liver disease.

Research Team

Eligibility Criteria

This trial is for adults aged 18 to 65 with alcohol-related liver disease. Specific eligibility criteria are not provided, but typically participants must meet certain health standards and may be excluded based on other medical conditions or treatments.

Inclusion Criteria

In the opinion of the investigator, there is a history of alcohol consumption compatible with either ALD or Met ALD

Able and willing to comply with all study assessments and adhere to the protocol schedule of activities

I am able to understand and sign the consent form for this study.

Exclusion Criteria

Body Mass Index (BMI) >35 kg/m2 at screening

My blood pressure is not well controlled.

I have had a TIPSS procedure.

Treatment Details

Interventions

• GSK4532990 (Other)

Trial Overview The study aims to test the safety and effectiveness of a new medication called GSK4532990 compared to a placebo in treating alcohol-related liver disease.

Participant Groups

Group I: GSK4532990 Dose 4 Experimental Treatment 1 Intervention

Group II: GSK4532990 Dose 3 Experimental Treatment 1 Intervention

Group III: GSK4532990 Dose 2 Experimental Treatment 1 Intervention

Group IV: GSK4532990 Dose 1 Experimental Treatment 1 Intervention

Group V: Placebo Placebo Group 1 Intervention

Who Is Running the Clinical Trial?

GlaxoSmithKline

Lead Sponsor

Trials

4,834

Recruited

8,389,000+

Headquarters

London, UK

Known For

Vaccines & Medicines

Top Products

**Advair (salmeterol, fluticasone propionate)**, **Shingrix (shingles vaccine)**, **Augmentin (amoxicillin/clavulanate potassium)**, **Ventolin (salbutamol sulfate)

Dame Emma Walmsley

GlaxoSmithKline

Chief Executive Officer since 2017

MA in Classics and Modern Languages from Oxford University

Dr. Hal Barron

GlaxoSmithKline

Chief Medical Officer since 2018

MD from Harvard Medical School